If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.50
Bid: 40.00
Ask: 43.00
Change: 0.50 (1.22%)
Spread: 3.00 (7.50%)
Open: 41.50
High: 41.50
Low: 41.50
Prev. Close: 41.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Replacement - Result of AGM and Directorate Change

15 Dec 2023 18:12

RNS Number : 0565X
Frontier IP Group plc
15 December 2023

The following replaces the announcement "Result of Annual General Meeting and Directorate Change" released on 15 December 2023 at 14:07 under RNS No: 0306X.

Resolution 10 incorrectly stated : (i) 0 votes against- this has been corrected to 111; and (ii) total votes cast (excluding votes withheld) of 28,801,720- this has been corrected to 28,801,831.

Nothing else has been amended. The full corrected version is below.

RNS

AIM: FIPP

15 December 2023

Frontier IP Group Plc

("Frontier IP" or the "Group")

Result of Annual General Meeting and Directorate Change

Frontier IP, a specialist in commercialising intellectual property, announces that at its annual general meeting ("AGM"), held earlier today, all resolutions were duly passed with the table below summarising proxy votes received.

The Company also confirms, as announced on 31 October 2023, that Andrew Richmond has not sought re-election as a director at today's annual general meeting and has stepped down from his role as Chairman with effect from today.

Dame Julia King, Baroness Brown of Cambridge has assumed the role of Chair following conclusion of today's AGM.

RESOLUTIONS

NO OF VOTES FOR

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

NO OF VOTES AGAINST

% OF VOTES CAST (EXCLUDING VOTES WITHELD)

TOTAL VOTES CAST (EXCLUDING VOTES WITHHELD)

NO OF VOTES WITHHELD

ORDINARY

1. To receive the audited consolidated financial statements of the Company and its subsidiaries for the year ended 30 June 2023, together with the reports of the Directors and the Auditor thereon.

28,798,831

100%

0

0%

28,798,831

7,001

2. To approve the report of the Board to the members on directors' remuneration for the year ended 30 June 2023.

24,016,521

83%

4,761,258

17%

28,777,779

28,053

3. To re-appoint Neil Crabb as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

3,000

0%

28,782,740

23,092

4. To re-appoint Jacqueline McKay as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

5. To re-appoint James Fish as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

6. To re-appoint Matthew White as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

7. To re-appoint David Holbrook as a Director of the Company and, being eligible, is offering himself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

8. To re-appoint Nigel Grierson as a Director of the Company and, being eligible, is offering himself for reappointment

28,779,740

100%

0

0%

28,779,740

26,092

9. To re-appoint Professor Dame Julia King, Baroness Brown of Cambridge as a Director of the Company and, being eligible, is offering herself for reappointment.

28,779,740

100%

0

0%

28,779,740

26,092

10. To resolve not to fill the vacancy created by the retirement of Andrew Richmond as a Director and Chairman of the Company at the AGM, in accordance with the Articles of Association of the Company

28,801,720

100%

111

0%

28,801,831

4,001

11. To re-appoint BDO LLP as auditor of the Company to hold office until the conclusion of the next general meeting at which financial statements are laid before shareholders.

28,797,617

100%

0

0%

28,797,617

8,215

12 To authorise the Directors to determine the auditor's remuneration

28,797,617

100%

4,214

0%

28,801,831

4,001

13. To authorise the directors to allot shares

28,779,740

100%

19,091

0%

28,798,831

7,001

SPECIAL

14. Authority to disapply pre-emption rights in connection with the allotment and issue of equity securities for cash in relation to (i) share option schemes; (ii) rights issue or similar offer; (iii) allotment of equity securities up to 10% of the issued share capital; or (iv) to the allotment of equity securities up to a nominal amount equal to 20%, such authority to be used only for the purposes of making a follow-on offer which the Board of the Company determines to be of a kind contemplated by paragraph 3 of Section 2B of the Statement of Principles on Disapplying Pre-Emption Rights.

23,213,401

81%

5,585,430

19%

28,798,831

7,001

15. Authority to disapply pre-emption rights to allot equity securities for cash.

27,929,775

97%

849,965

3%

28,779,740

26,092

16. Authority to purchase own shares on market.

24,461,860

100%

7,850

0%

24,469,710

4,336,122

Votes which have been cast at the discretion of the Chairman have been counted as votes for the resolutions. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution.

ENQUIRIES

Frontier IP Group Plc

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

T: 020 3968 7815

neil@frontierip.co.uk

M: 07464 546 025

andrew.johnson@frontierip.co.uk

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

T: 0203 328 5656

Singer Capital Markets (Broker)

Harry Gooden / James Fischer

T: 0207 496 3000

ABOUT FRONTIER IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCMZMMZRKGGFZM
Date   Source Headline
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product
9th Dec 20212:33 pmRNSResult of AGM
29th Nov 20217:00 amRNSTVG - milestone in development of COVID-19 vaccine
9th Nov 20217:00 amRNSPosting of Annual Accounts and Notice of AGM
28th Oct 20217:00 amRNSDirectorate Change
28th Oct 20217:00 amRNSFinal Results
15th Oct 20217:00 amRNSPublication of newsletter
1st Oct 20217:59 amRNSPricing of IPO of Exscientia in the United States
30th Sep 20217:00 amRNSCamGraPhIC raises £1.6 million
27th Sep 20213:56 pmRNSUpdate on proposed IPO of Exscientia
24th Sep 20217:00 amRNSHolding(s) in Company
13th Sep 20217:00 amRNSExscientia - Statement filed for proposed IPO
8th Sep 20211:24 pmRNSExscientia enters $70M collaboration
8th Jul 20217:00 amRNSCamGraPhIC loan facility of up to £1.5 million
15th Jun 20217:00 amRNSPulsiv appoints Adam Westcott as CFO
14th Jun 20217:00 amRNSNandi Proteins appoints David Flower as CEO
11th Jun 20217:00 amRNSPublication of newsletter
24th May 20217:00 amRNSPulsiv complete £1.5m fundraising and appoints CEO
19th May 202111:53 amRNSExscientia collaboration with Bristol Myers Squibb
6th May 20217:00 amRNSThe Vaccine Group appoints Jeremy Salt as CEO
30th Apr 20211:58 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.